Загрузка...

AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

BACKGROUND: MSB11022 is a proposed adalimumab biosimilar. OBJECTIVES: To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. METHODS: AURIEL‐PsO was a double‐blind randomized controlled equivalence trial, in which patients with moderate‐to‐severe chronic plaque‐typ...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Dermatol
Главные авторы: Hercogová, J., Papp, K.A., Chyrok, V., Ullmann, M., Vlachos, P., Edwards, C.J.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2019
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027805/
https://ncbi.nlm.nih.gov/pubmed/31206593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18220
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!